Photo: Tatsiana Volkava / Moment / Getty Images
In a major clinical trial, the medication Wegovy, known for its weight loss benefits, has shown potential in treating the serious liver disease metabolic dysfunction-associated steatohepatitis (MASH), more commonly known as fatty liver disease. Led by Dr. Arun Sanyal of Virginia Commonwealth University and Dr. Philip Newsome of King’s College London, the study suggests that semaglutide, the active ingredient in Wegovy, can halt and even reverse MASH, which affects millions globally.
The trial, detailed in the New England Journal of Medicine, involved 800 participants, with 534 receiving semaglutide and 266 a placebo. Over 72 weeks, those treated with semaglutide showed improvement in liver health and metabolic issues, crucial for managing MASH. Dr. Sanyal noted, "The results provide strong evidence that semaglutide can help patients by improving liver health and addressing underlying metabolic issues."
MASH, affecting an estimated 15 million Americans, is linked to obesity, type 2 diabetes, and high blood pressure. It can lead to severe liver conditions, including cirrhosis and liver failure. Currently, only one FDA-approved treatment exists, highlighting the need for new options.
Semaglutide, a GLP-1 receptor agonist, is already approved for weight loss and blood sugar control. Its potential to treat MASH could offer a new therapeutic avenue, pending regulatory approval. The trial's second phase will track 1,200 participants over five years to assess long-term effects.